Immunological hallmarks of jc virus replication in multiple sclerosis patients on long-term natalizumab therapy

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 6055-6059

  Hendel Chavez, Houria ^a,b   Herve, Marie Ghislaine de Goër de ^a,b   Giannesini, Claire ^c,d   Mazet, Anne Aurélie ^e   Papeix, Caroline ^f   Louapre, Céline ^f   Chardain, Audrey ^c,d   Boutarfa, Nassima ^a,b   Théaudin, Marie ^e,g   Adams, David ^e,g   Gasnault, Jacques ^b,e   Stankoff, Bruno ^c,d   Taoufika, Yassine ^b,g  

^a Hôpitaux Universitaires Paris Sud   (France)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e BICÊTRE HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CHRONIC DRUG ADMINISTRATION; FEMALE; HUMAN; HUMAN CELL; JC VIRUS; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 84877341390     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00131-13     Document Type: Article

References (25)

1. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. 2010. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat. Rev. Neurol. 6:667- 679.
2. Gasnault J, Taoufik Y. 2006. New trends in progressive multifocal leukoencephalopathy. Rev. Neurol. (Paris) 162:43-56.
3. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. 2010. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9:438-446.
4. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369 -374.
5. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375-381.
6. Major EO. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61:35- 47.
7. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353:362-368.
8. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, Dunachie SJ, Moorthy VS, McConkey SJ, Gilbert SC, Hill AV. 2005. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175:5675- 5680.
9. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, Plebanski M, Akinwunmi P, Everaere S, Watkins KR, Voss G, Tornieporth N, Alloueche A, Greenwood BM, Kester KE, McAdam KP, Cohen J, Hill AV. 2004. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10:406-410.
10. Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F, Klenerman P, Hill AV. 2009. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128:83-91.
11. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ. 2009. Asymptomatic reactivation of JCvirus in patients treated with natalizumab. N. Engl. J. Med. 361:1067-1074.
12. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
13. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y. 1990. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J. Infect. Dis. 161:1128-1133.
14. Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS. 1993. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and uninfected subjects. J. Infect. Dis. 167:13-20.
15. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R, Calvo MG, Ferrante P. 2007. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J. Med. Virol. 79:408-412.
16. Bayliss J, Karasoulos T, Bowden S, Glogowski I, McLean CA. 2011. Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology 43:362-367.
17. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M. 2010. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68:295-303.
18. Amanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915.
19. Manz RA, Hauser AE, Hiepe F, Radbruch A. 2005. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23:367-386.
20. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA. 2010. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 9:264- 272.
21. Tan CS, Ellis LC, Wuthrich C, Ngo L, Broge TA, Jr, Saint-Aubyn J, Miller JS, Koralnik IJ. 2010. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84:9200 -9209.
22. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ, van der Valk P, Ravid R, Rensing S, Boon L, BAt Hart Laman JD. 2002. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 169:5415-5423.
23. Karman J, Ling C, Sandor M, Fabry Z. 2004. Initiation of immune responses in brain is promoted by local dendritic cells. J. Immunol. 173: 2353-2361.
24. Walter L, Albert ML. 2007. Cutting edge: cross-presented intracranial antigen primes CD8 + T cells. J. Immunol. 178:6038-6042.
25. Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y. 2011. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967. doi:10.1371/journal.pone.0020967.